PMID- 1418775
OWN - NLM
STAT- MEDLINE
DCOM- 19921204
LR  - 20190718
IS  - 0269-9370 (Print)
IS  - 0269-9370 (Linking)
VI  - 6
IP  - 8
DP  - 1992 Aug
TI  - Expression of activation antigens, HLA-DR and CD38, on CD8 lymphocytes during 
      HIV-1 infection.
PG  - 793-7
AB  - OBJECTIVE: To study the expression of the activation markers human leukocyte 
      antigen (HLA)-DR and CD38 antigen on CD8+ T-lymphocytes in HIV-infected subjects 
      and HIV-negative controls. DESIGN: Two- and three-colour flow-cytometric 
      analysis. METHODS: Fresh peripheral venous blood was obtained from 16 
      HIV-infected subjects, representing four different stages of HIV disease, and 
      from six HIV-negative controls. Three-colour lymphocyte immunophenotyping was 
      performed using peridinyl chlorophyll-A protein (PerCP)-conjugated anti-CD8 
      monoclonal antibody (MAb) in combination with anti-HLA-DR (phycoerythrin) and 
      anti-CD38 (fluorescein isothiocyanate) MAb. RESULTS: The relative percentage of 
      the lymphocyte populations thus defined differed between HIV-negative and 
      HIV-positive subjects and between HIV-infected subjects at different clinical 
      stages of disease. Simultaneous expression of HLA-DR and CD38 within the CD8 
      T-lymphocyte compartment increased from 8% in controls to 49% in asymptomatic 
      HIV-infected subjects (P less than 0.005). Symptomatic patients differed from 
      asymptomatic seropositives by a further increase in the HLA-DR+ CD38+ CD8 subset. 
      In AIDS patients, the HLA-DR+ CD38- CD8 subset decreased (P less than 0.05) and 
      the HLA-DR- CD38+ CD8 subset increased (P less than 0.05), compared with the 
      other HIV disease stage patients. CONCLUSION: There is a stage-associated pattern 
      of HLA-DR and CD38 expression on CD8 T-lymphocytes during HIV infection; specific 
      phenotypic patterns may have functional correlates in the host response to the 
      virus.
FAU - Kestens, L
AU  - Kestens L
AD  - Laboratory of Pathology and Immunology, Institute of Tropical Medicine, Antwerp, 
      Belgium.
FAU - Vanham, G
AU  - Vanham G
FAU - Gigase, P
AU  - Gigase P
FAU - Young, G
AU  - Young G
FAU - Hannet, I
AU  - Hannet I
FAU - Vanlangendonck, F
AU  - Vanlangendonck F
FAU - Hulstaert, F
AU  - Hulstaert F
FAU - Bach, B A
AU  - Bach BA
LA  - eng
PT  - Journal Article
PL  - England
TA  - AIDS
JT  - AIDS (London, England)
JID - 8710219
RN  - 0 (Antigens, CD)
RN  - 0 (Antigens, Differentiation)
RN  - 0 (CD8 Antigens)
RN  - 0 (HLA-DR Antigens)
RN  - 0 (Membrane Glycoproteins)
RN  - EC 3.2.2.5 (ADP-ribosyl Cyclase)
RN  - EC 3.2.2.5 (CD38 protein, human)
RN  - EC 3.2.2.6 (ADP-ribosyl Cyclase 1)
SB  - IM
MH  - ADP-ribosyl Cyclase
MH  - ADP-ribosyl Cyclase 1
MH  - Antigens, CD/*blood
MH  - Antigens, Differentiation/*blood
MH  - CD8 Antigens/blood
MH  - Fluorescent Antibody Technique
MH  - HIV Infections/*immunology
MH  - *HIV-1
MH  - HLA-DR Antigens/*blood
MH  - Humans
MH  - Membrane Glycoproteins
MH  - T-Lymphocytes, Cytotoxic/*immunology
EDAT- 1992/08/01 00:00
MHDA- 1992/08/01 00:01
CRDT- 1992/08/01 00:00
PHST- 1992/08/01 00:00 [pubmed]
PHST- 1992/08/01 00:01 [medline]
PHST- 1992/08/01 00:00 [entrez]
AID - 10.1097/00002030-199208000-00004 [doi]
PST - ppublish
SO  - AIDS. 1992 Aug;6(8):793-7. doi: 10.1097/00002030-199208000-00004.